Phaseline

Targets › COL7A1

COL7A1 (Collagen alpha-1(VII) chain): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Other, Oncology, Immunology; next expected readout Dec 2026.

Stratified squamous epithelial basement membrane protein that forms anchoring fibrils which may contribute to epithelial basement membrane organization and adherence by interacting with extracellular matrix (ECM) proteins such as type IV collagen. (UniProt, Q02388)

Open in Phaseline: the race on COL7A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Krystal BiotechKB803
Replication-defective, non-integrating HSV-1 expressing human collagen VII protein
COL7A1Phase 3Dystrophic Epidermolysis BullosaDec 2026
Stanford UniversityBVEC (Beremagene Geperpavec)
COL7A1 gene therapy; induces C7 (type VII collagen) expression
COL7A1Phase 2Squamous Cell CarcinomaFeb 2027
CHU de Quebec-Universite LavalGenetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-
Retroviral vector-mediated gene therapy delivering COL7A1 to patient-derived keratinocytes
COL7A1Phase 1RDEBDec 2030
Fundación DEBRA Chile, Niños Piel de CristalELK-003 (Standarized Amniotic Fluid Secretome Eye Drops)
Amniotic fluid secretome containing extracellular matrix proteins (collagen type VII, lami
COL7A1, LAMA3Phase 1Junctional Epidermolysis Bullosa–

Conditions

Junctional Epidermolysis Bullosa (1) Dystrophic Epidermolysis Bullosa (1) Squamous Cell Carcinoma (1) RDEB (1)

Modalities

protein or peptide (3), other (1)

Companies

Fundación DEBRA Chile, Niños Piel de Cristal (1) Krystal Biotech (1) Stanford University (1) CHU de Quebec-Universite Laval (1)

Related targets

LAMA3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.